In the overall population (n = 186), median PFS was 18.7 weeks in patients with BM and 19.4 weeks in patients without BM (HR 0.98 [95% CI: 0.71-1.35], P = 0.88). Among patients with BM, median overall PFS was significantly prolonged in patients who did not use prior capecitabine (28.3 weeks vs 14.0 weeks, P = 0.009), but brain PFS was not statistically significantly different between these two subsets (31.4 weeks vs 25.6 weeks, P = 0.54; Figure 1).
Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea
http://www.biomedcentral.com/1471-2407/12/322